ALIROCUMAB IN HIGH-RISK PATIENTS WITH BASELINE LDL-C ≥160 MG/DL: FINDINGS FROM THE COMPASSIONATE USE PROGRAM

被引：0
|
作者：
Glueck, Charles J.
Brown, Alan
Goldberg, Anne
McKenney, James
Kantaros, Louis
Stewart, John
Elassal, Joseph
Koren, Andrew
机构：
[1] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[2] Sanofi, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(17)33544-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1203-309
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [41] Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c
    Hajer, G. R.
    van der Graaf, Y.
    Bots, M. L.
    Algra, A.
    Visseren, F. L. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (08) : 680 - 688
  • [42] LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy
    Ashton, Veronica
    Zhang, Qiaoyi
    Zhang, Ning Jackie
    Zhao, Changgeng
    Ramey, Dena Rosen
    Neff, David
    Tershakovec, Andrew M.
    Marrett, Elizabeth
    CLINICAL THERAPEUTICS, 2014, 36 (05) : 792 - 799
  • [43] THE REAL EXPERIENCE OF REACHING AN EXTREMELY LOW LDL-C LEVEL IN HIGH RISK PATIENTS
    Korneva, V. A.
    Kuznetsova, T.
    ATHEROSCLEROSIS, 2022, 355 : E175 - E175
  • [44] Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels * , **
    Bianconi, Vanessa
    Banach, Maciej
    Pirro, Matteo
    TRENDS IN CARDIOVASCULAR MEDICINE, 2021, 31 (04) : 205 - 215
  • [45] COST-EFFECTIVENESS OF STATIN THERAPY FOR SECONDARY PREVENTION AMONG PATIENTS WITH CORONARY ARTERY DISEASE WITH BASELINE LDL-C LEVEL OF 70-100 MG/DL IN TAIWAN
    Lin, F.
    Shau, W.
    Wen, Y.
    Li, J. Z.
    Fung, S. S.
    Inocencio, T.
    Gao, X.
    Yeh, H.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [46] TREATMENT PATTERNS AND LDL-C CONTROL IN VERY HIGH-RISK PATIENTS RECEIVING LIPID-LOWERING THERAPY IN THE UNITED KINGDOM
    Beaini, Y.
    Danese, M.
    Sidelnikov, E.
    Villa, G.
    Catterick, D.
    Iqbal, M.
    Gleeson, M.
    Lubeck, D.
    Patel, J.
    VALUE IN HEALTH, 2020, 23 : S499 - S500
  • [47] Effects of Achieving LDL-Cholesterol Levels <70 mg/dL With Simvastatin or Atorvastatin on Steroidogenesis in High-Risk Diabetic Patients
    Berberoglu, Zehra
    Guvener, Nigun
    Asik, Mehmet
    Yazici, Ayse Canan
    Bayraktar, Nilufer
    ENDOCRINOLOGIST, 2009, 19 (03): : 102 - 107
  • [48] Cordova Formula, A Better Alternative to Martin's Formula for the Calculation of LDL-C in Patients with TG above 350 mg/dL
    Tomo, Sojit
    Sankanagoudar, Shrimanjunath
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2022, 50 (04): : 308 - 309
  • [49] EFFECT OF ROSUVASTATIN AND ATORVASTATIN DOSE ON LDL-C <70MG/DL GOAL ATTAINMENT IN PATIENTS WITH DIABETES MELLITUS: RESULTS FROM VOYAGER
    Karlson, B. W.
    Barter, P. J.
    Palmer, M. K.
    Lundman, P.
    Nicholls, S. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 164 - 164
  • [50] Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom
    Cao, Xiting
    Ejzykowicz, Flavia
    Ramey, Dena R.
    Sajjan, Shiva
    Ambegaonkar, Baishali M.
    Mavros, Panagiotis
    Tunceli, Kaan
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 804 - 815
12345